Dapoxetine hydrochloride

Pfizer Inc., leveraging its extensive urology portfolio including sildenafil and tadalafil, has integrated dapoxetine licensing into comprehensive sexual dysfunction platforms, capturing 18% of the pharmaceutical PE treatment market segment.

Side Effects of Dapoxetine

Emerging digital health competitors including Ro, Hims, and Roman collectively generated estimated $340 million in PE treatment revenues through subscription platforms and direct-to-consumer models during 2025. Behavioral health platforms including BetterHelp and Talkspace captured approximately $210 million in PE treatment-related revenues through licensed therapist networks. Device manufacturers including Stud 100 parent company maintained market presence with $78 million in annual PE-related device revenues, while emerging device companies remained largely pre-commercial or early-stage revenue generation. Branded dapoxetine commanded premium pricing of $1.80 to $2.40 USD per dose through 2025, while generic equivalents were priced at $0.48 to $0.72 USD, representing 70% to 78% cost reduction and driving generic market capture from 28% in 2020 to 54% by 2025. Branded formulations maintain competitive positioning through superior marketing, established physician relationships, and patient preference driven by perceived superior quality, though clinical efficacy remains equivalent between branded and generic dapoxetine formulations across randomized trials.

Depression and anxiety

Market Share 2025: 58.4%Valuation: $2.45 billionCAGR (2025-2033): 9.1%Includes: Dapoxetine, SSRIs, topical anesthetics, combination therapiesKey Driver: FDA approvals, insurance coverage expansion, telehealth accessibility Market Share 2025: 23.8%Valuation: $998 millionCAGR (2025-2033): 10.4%Includes: Cognitive-behavioral therapy, sex therapy, couples counseling, start-stop techniqueKey Driver: Patient preference, improved therapist training, insurance coverage expansion Market Share 2025: 17.8%Valuation: $746 millionCAGR (2025-2033): 11.4%Includes: Topical anesthetic devices, mechanical solutions, vibration therapy, wearablesKey Driver: Innovation, non-systemic safety profiles, technological advancement Market Share 2025: 29.4%Valuation: $1.23 billionCAGR (2025-2033): 8.2%Services: Specialty sexual medicine departments, multidisciplinary teams, complex case managementOpportunity: Telemedicine expansion, integrated care coordination Market Share 2025: 34.2%Valuation: $1.44 billionCAGR (2025-2033): 10.6%Services: Specialized sexual medicine, urology practices, dermatology integrationOpportunity: Network expansion, emerging market penetration Market Share 2025: 19.8%Valuation: $832 millionCAGR (2025-2033): 15.2%Services: Digital consultations, direct fulfillment, subscription models, convenience accessOpportunity: Regulatory expansion, payment innovation Market Share 2025: 16.6%Valuation: $696 millionCAGR (2025-2033): 4.1%Services: Traditional brick-and-mortar operations, counseling, in-person consultationsOpportunity: Hybrid clinic models, underserved populations Market Share 2025: 67.2%Valuation: $2.82 billionCAGR (2025-2033): 10.1%Demographics: Ages 18-70, expanding treatment-seeking behavior, improved awarenessPreference: Telehealth adoption increasing from 34% in 2025 to projected 52% by 2033 Market Share 2025: 32.8%Valuation: $1.38 billionCAGR (2025-2033): 9.2%Practitioners: Physicians, urologists, sex therapists, psychiatrists, nursing specialistsGrowth: Expanding training programs, clinical research, integrated care models Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms UsedChapter 3 Research MethodologyChapter 4 Premature Ejaculation Treatment Market Overview4.1 Introduction4.1.1 Market Taxonomy4.1.2 Market Definition4.1.3 Macro-Economic Factors Impacting the Market Growth4.2 Premature Ejaculation Treatment Market Dynamics4.2.1 Market Drivers4.2.2 Market Restraints4.2.3 Market Opportunity4.3 Premature Ejaculation Treatment Market - Supply Chain Analysis4.3.1 List of Key Suppliers4.3.2 List of Key Distributors4.3.3 List of Key Consumers4.4 Key Forces Shaping the Premature Ejaculation Treatment Market4.4.1 Bargaining Power of Suppliers4.4.2 Bargaining Power of Buyers4.4.3 Threat of Substitution4.4.4 Threat of New Entrants4.4.5 Competitive Rivalry4.5 Global Premature Ejaculation Treatment Market Size & Forecast, 2025-20344.5.1 Premature Ejaculation Treatment Market Size and Y-o-Y Growth4.5.2 Premature Ejaculation Treatment Market Absolute $ OpportunityChapter 5 Global Premature Ejaculation Treatment Market Analysis and Forecast By Treatment Type5.1 Introduction5.1.1 Key Market Trends & Growth Opportunities By Treatment Type5.1.2 Basis Point Share (BPS) Analysis By Treatment Type5.1.3 Absolute $ Opportunity Assessment By Treatment Type5.2 Premature Ejaculation Treatment Market Size Forecast By Treatment Type5.2.1 Pharmaceutical5.2.2 Behavioral Therapy5.2.3 Devices5.3 Market Attractiveness Analysis By Treatment TypeChapter 6 Global Premature Ejaculation Treatment Market Analysis and Forecast By Distribution Channel6.1 Introduction6.1.1 Key Market Trends & Growth Opportunities By Distribution Channel6.1.2 Basis Point Share (BPS) Analysis By Distribution Channel6.1.3 Absolute $ Opportunity Assessment By Distribution Channel6.2 Premature Ejaculation Treatment Market Size Forecast By Distribution Channel6.2.1 Hospitals6.2.2 Clinics6.2.3 Online Pharmacies6.2.4 Retail Pharmacies6.3 Market Attractiveness Analysis By Distribution ChannelChapter 7 Global Premature Ejaculation Treatment Market Analysis and Forecast By End-User7.1 Introduction7.1.1 Key Market Trends & Growth Opportunities By End-User7.1.2 Basis Point Share (BPS) Analysis By End-User7.1.3 Absolute $ Opportunity Assessment By End-User7.2 Premature Ejaculation Treatment Market Size Forecast By End-User7.2.1 Men7.2.2 Healthcare Providers7.3 Market Attractiveness Analysis By End-UserChapter 8 Global Premature Ejaculation Treatment Market Analysis and Forecast by Region8.1 Introduction8.1.1 Key Market Trends & Growth Opportunities By Region8.1.2 Basis Point Share (BPS) Analysis By Region8.1.3 Absolute $ Opportunity Assessment By Region8.2 Premature Ejaculation Treatment Market Size Forecast By Region8.2.1 North America8.2.2 Europe8.2.3 Asia Pacific8.2.4 Latin America8.2.5 Middle East & Africa (MEA)8.3 Market Attractiveness Analysis By RegionChapter 9 Coronavirus Disease (COVID-19) Impact9.1 Introduction9.2 Current & Future Impact Analysis9.3 Economic Impact Analysis9.4 Government Policies9.5 Investment ScenarioChapter 10 North America Premature Ejaculation Treatment Analysis and Forecast10.1 Introduction10.2 North America Premature Ejaculation Treatment Market Size Forecast by Country10.2.1 U.S.10.2.2 Canada10.3 Basis Point Share (BPS) Analysis by Country10.4 Absolute $ Opportunity Assessment by Country10.5 Market Attractiveness Analysis by Country10.6 North America Premature Ejaculation Treatment Market Size Forecast By Treatment Type10.6.1 Pharmaceutical10.6.2 Behavioral Therapy10.6.3 Devices10.7 Basis Point Share (BPS) Analysis By Treatment Type10.8 Absolute $ Opportunity Assessment By Treatment Type10.9 Market Attractiveness Analysis By Treatment Type10.10 North America Premature Ejaculation Treatment Market Size Forecast By Distribution Channel10.10.1 Hospitals10.10.2 Clinics10.10.3 Online Pharmacies10.10.4 Retail Pharmacies10.11 Basis Point Share (BPS) Analysis By Distribution Channel10.12 Absolute $ Opportunity Assessment By Distribution Channel10.13 Market Attractiveness Analysis By Distribution Channel10.14 North America Premature Ejaculation Treatment Market Size Forecast By End-User10.14.1 Men10.14.2 Healthcare Providers10.15 Basis Point Share (BPS) Analysis By End-User10.16 Absolute $ Opportunity Assessment By End-User10.17 Market Attractiveness Analysis By End-UserChapter 11 Europe Premature Ejaculation Treatment Analysis and Forecast11.1 Introduction11.2 Europe Premature Ejaculation Treatment Market Size Forecast by Country11.2.1 Germany11.2.2 France11.2.3 Italy11.2.4 U.K.11.2.5 Spain11.2.6 Russia11.2.7 Rest of Europe11.3 Basis Point Share (BPS) Analysis by Country11.4 Absolute $ Opportunity Assessment by Country11.5 Market Attractiveness Analysis by Country11.6 Europe Premature Ejaculation Treatment Market Size Forecast By Treatment Type11.6.1 Pharmaceutical11.6.2 Behavioral Therapy11.6.3 Devices11.7 Basis Point Share (BPS) Analysis By Treatment Type11.8 Absolute $ Opportunity Assessment By Treatment Type11.9 Market Attractiveness Analysis By Treatment Type11.10 Europe Premature Ejaculation Treatment Market Size Forecast By Distribution Channel11.10.1 Hospitals11.10.2 Clinics11.10.3 Online Pharmacies11.10.4 Retail Pharmacies11.11 Basis Point Share (BPS) Eli Lilly and Company has expanded sexual dysfunction treatment capabilities through tadalafil-based approaches and emerging novel compounds, positioning for competitive growth through the forecast period. Bayer AG, GlaxoSmithKline, and Merck & Co. maintain presence through SSRI formulations and licensed generic agreements, collectively controlling approximately 24% of the pharmaceutical PE treatment market. Generic manufacturers including Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, and Viatris have expanded market presence through low-cost dapoxetine and SSRI generic formulations, capturing 34% market share and substantially compressing branded manufacturer pricing power. Emerging pharmaceutical competitors from India and China, including companies like Cadila Healthcare and China Biologic Products, have entered PE treatment markets through generic offerings and novel formulations, intensifying competitive pressure. Competition within behavioral therapy markets remains fragmented among independent sex therapists, psychological practices, and emerging digital therapy platforms. Traditional private practice sex therapists and licensed marriage and family therapists operate as local competitors with limited geographic reach, though professional associations including the American Association of Sexuality Educators, Counselors and Therapists (AASECT) provide quality standards and patient referral mechanisms. Digital therapy platforms including BetterHelp, Talkspace, and Psychology Today's therapist marketplace have introduced scalable behavioral PE treatment options, competing directly against traditional individual therapy practices through convenience and potentially lower costs. Large telehealth platforms including Teladoc and Amwell have incorporated behavioral health specialists as differentiating offerings within comprehensive sexual health programs. Hospital and clinic-based sexual medicine departments compete through integrated behavioral and pharmaceutical management, leveraging specialist expertise as competitive advantage. Academic institutions including Mayo Clinic, Johns Hopkins University, and University of California San Francisco maintain competitive advantage through clinical research leadership and specialized training programs, attracting high-complexity patients willing to travel for expert consultation.

The device segment competitive landscape remains highly fragmented with numerous small manufacturers and niche players. Established topical anesthetic brands including Stud 100 and Promescent maintain market presence through decades of brand recognition, though facing competition from emerging private label topical products sold through online retailers.

Major sexual wellness companies including LELO, We-Vibe, and Adam & Eve have expanded from reproductive pleasure devices into PE-directed therapeutic options, leveraging existing distribution tadalafil with dapoxetine online channels and brand awareness.

Buy Dapoxetine Tablets

Pfizer Inc., leveraging its extensive urology portfolio including sildenafil and tadalafil, has integrated dapoxetine licensing into comprehensive sexual dysfunction platforms, capturing 18% of the pharmaceutical PE treatment market segment. Eli Lilly and Company has expanded sexual dysfunction treatment capabilities through tadalafil-based approaches and emerging novel compounds, positioning for competitive growth through the forecast period. Bayer AG, GlaxoSmithKline, and Merck & Co. maintain presence through SSRI formulations and licensed generic agreements, collectively controlling approximately 24% of the pharmaceutical PE treatment market. Generic manufacturers including Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, and Viatris have expanded market presence through low-cost dapoxetine and SSRI generic formulations, capturing 34% market share and substantially compressing branded manufacturer pricing power.

Product Avanafil CAS#330784-47-9; Vildagliptin CAS#274901-16-5

Emerging pharmaceutical competitors from India and China, including companies like Cadila Healthcare and China Biologic Products, have entered PE treatment markets through generic offerings and novel formulations, intensifying competitive pressure. Competition within behavioral therapy markets remains fragmented among independent sex therapists, psychological practices, and emerging digital therapy platforms. Traditional private practice sex therapists and licensed marriage and family therapists operate as local competitors with limited geographic reach, though professional associations including the American Association of Sexuality Educators, Counselors and Therapists (AASECT) provide quality standards and patient referral mechanisms. Digital therapy platforms including BetterHelp, Talkspace, and Psychology Today's therapist marketplace have introduced scalable behavioral PE treatment options, competing directly against traditional individual therapy practices through convenience and potentially lower costs. Large telehealth platforms including Teladoc and Amwell have incorporated behavioral health specialists as differentiating offerings within comprehensive sexual health programs. Medical device manufacturers including Boston Scientific and Abbott have initiated exploration of PE treatment devices through partnership and acquisition opportunities, bringing substantial manufacturing and regulatory expertise.

• Dapoxetine's popularity increased among young Spanish men.
• The drug is often used with counseling for better results.
• Spain has educational campaigns about premature ejaculation treatments.
• Dapoxetine's cost-effectiveness makes it attractive in Spain.
• Many online pharmacies sell dapoxetine with a prescription.
• Dapoxetine is considered a first-line treatment for PE in Spain.
• Patients should report adverse effects to their doctor promptly.

Emerging digital and wearable device manufacturers remain largely venture-backed startups with limited market penetration but substantial innovation pipelines; companies including Kiiroo and Skyn have developed interconnected devices with biofeedback capabilities targeting PE populations.

What Is Dapoxetine (Priligy)?

Chemical Formula

Regulatory pathways for device classification remain evolving; most PE-related devices operate in the unregulated or minimally-regulated supplement category, creating opportunities for rapid market entry but limiting clinical validation potential. Top competitors in the global premature ejaculation treatment market during 2025 included Takeda Pharmaceutical commanding $127 million in dapoxetine-specific revenues, Pfizer leveraging integrated sexual dysfunction portfolios generating estimated $284 million in PE-related revenues, Eli Lilly with $89 million in PE treatment-related business, and Bayer AG with $76 million through integrated sildenafil-tadalafil combinations. Generic manufacturers Sun Pharmaceutical, Teva, and Viatris collectively generated approximately $410 million through low-cost generic formulations.

Safety and tolerability

Hospital and clinic-based sexual medicine departments compete through integrated behavioral and pharmaceutical management, leveraging specialist expertise as competitive advantage. Academic institutions including Mayo Clinic, Johns Hopkins University, and University of California San Francisco maintain competitive advantage through clinical research leadership and specialized training programs, attracting high-complexity patients willing to travel for expert consultation. The device segment competitive landscape remains highly fragmented with numerous small manufacturers and niche players. Established topical anesthetic brands including Stud 100 and Promescent maintain market presence through decades of brand recognition, though facing competition from emerging private label topical products sold through online retailers. Major sexual wellness companies including LELO, We-Vibe, and Adam & Eve have expanded from reproductive pleasure devices into PE-directed therapeutic options, leveraging existing distribution tadalafil with dapoxetine online channels and brand awareness.

Mechanism of action

Medical device manufacturers including Boston Scientific and Abbott have initiated exploration of PE treatment devices through partnership and acquisition opportunities, bringing substantial manufacturing and regulatory expertise. Emerging digital and wearable device manufacturers remain largely venture-backed startups with limited market penetration but substantial innovation pipelines; companies including Kiiroo and Skyn have developed interconnected devices with biofeedback capabilities targeting PE populations. Regulatory pathways for device classification remain evolving; most PE-related devices operate in the unregulated or minimally-regulated supplement category, creating opportunities for rapid market entry but limiting clinical validation potential. Top competitors in the global premature ejaculation treatment market during 2025 included Takeda Pharmaceutical commanding $127 million in dapoxetine-specific revenues, Pfizer leveraging integrated sexual dysfunction portfolios generating estimated $284 million in PE-related revenues, Eli Lilly with $89 million in PE treatment-related business, and Bayer AG with $76 million through integrated sildenafil-tadalafil combinations. Generic manufacturers Sun Pharmaceutical, Teva, and Viatris collectively generated approximately $410 million through low-cost generic formulations. Emerging digital health competitors including Ro, Hims, and Roman collectively generated estimated $340 million in PE treatment revenues through subscription platforms and direct-to-consumer models during 2025. Behavioral health platforms including BetterHelp and Talkspace captured approximately $210 million in PE treatment-related revenues through licensed therapist networks. Device manufacturers including Stud 100 parent company maintained market presence with $78 million in annual PE-related device revenues, while emerging device companies remained largely pre-commercial or early-stage revenue generation.

• Patient privacy is protected under Spanish data protection laws (LOPDGDD).
• Medical discussions about PE are confidential between you and your doctor.
• You have the right to access your medical records regarding this prescription.
• Online consultations for PE are available but must be with licensed professionals.
• Be cautious of platforms that issue prescriptions after only a questionnaire.
• A legitimate online service will require a virtual consultation with a doctor.
• Ensure the online pharmacy is registered with the Spanish Council of Pharmacists.
• Read reviews and verify contact information before using an online service.
• Trust your instincts; if an offer seems too good to be true, it probably is.

Branded dapoxetine commanded premium pricing of $1.80 to $2.40 USD per dose through 2025, while generic equivalents were priced at $0.48 to $0.72 USD, representing 70% to 78% cost reduction and driving generic market capture from 28% in 2020 to 54% by 2025.

Over Dose

Molecular Weight

Branded formulations maintain competitive positioning through superior marketing, established physician relationships, and patient preference driven by perceived superior quality, though clinical efficacy remains equivalent between branded and generic dapoxetine formulations across randomized trials.

• The availability of dapoxetine has positively impacted men's health in Spain.
• Medical guidelines specify suitable candidates for dapoxetine therapy.
• Dapoxetine is classified as a prescription medication in Spain.
• The drug's side effect profile is well understood among physicians.
• Spanish men are increasingly seeking treatment options like dapoxetine.
• It is important to maintain good communication with healthcare providers.
• Using dapoxetine responsibly ensures optimal benefits and safety.

Market Share 2025: 58.4%Valuation: $2.45 billionCAGR (2025-2033): 9.1%Includes: Dapoxetine, SSRIs, topical anesthetics, combination therapiesKey Driver: FDA approvals, insurance coverage expansion, telehealth accessibility Market Share 2025: 23.8%Valuation: $998 millionCAGR (2025-2033): 10.4%Includes: Cognitive-behavioral therapy, sex therapy, couples counseling, start-stop techniqueKey Driver: Patient preference, improved therapist training, insurance coverage expansion Market Share 2025: 17.8%Valuation: $746 millionCAGR (2025-2033): 11.4%Includes: Topical anesthetic devices, mechanical solutions, vibration therapy, wearablesKey Driver: Innovation, non-systemic safety profiles, technological advancement Market Share 2025: 29.4%Valuation: $1.23 billionCAGR (2025-2033): 8.2%Services: Specialty sexual medicine departments, multidisciplinary teams, complex case managementOpportunity: Telemedicine expansion, integrated care coordination Market Share 2025: 34.2%Valuation: $1.44 billionCAGR (2025-2033): 10.6%Services: Specialized sexual medicine, urology practices, dermatology integrationOpportunity: Network expansion, emerging market penetration Market Share 2025: 19.8%Valuation: $832 millionCAGR (2025-2033): 15.2%Services: Digital consultations, direct fulfillment, subscription models, convenience accessOpportunity: Regulatory expansion, payment innovation Market Share 2025: 16.6%Valuation: $696 millionCAGR (2025-2033): 4.1%Services: Traditional brick-and-mortar operations, counseling, in-person consultationsOpportunity: Hybrid clinic models, underserved populations Market Share 2025: 67.2%Valuation: $2.82 billionCAGR (2025-2033): 10.1%Demographics: Ages 18-70, expanding treatment-seeking behavior, improved awarenessPreference: Telehealth adoption increasing from 34% in 2025 to projected 52% by 2033 Market Share 2025: 32.8%Valuation: $1.38 billionCAGR (2025-2033): 9.2%Practitioners: Physicians, urologists, sex therapists, psychiatrists, nursing specialistsGrowth: Expanding training programs, clinical research, integrated care models Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms UsedChapter 3 Research MethodologyChapter 4 Premature Ejaculation Treatment Market Overview4.1 Introduction4.1.1 Market Taxonomy4.1.2 Market Definition4.1.3 Macro-Economic Factors Impacting the Market Growth4.2 Premature Ejaculation Treatment Market Dynamics4.2.1 Market Drivers4.2.2 Market Restraints4.2.3 Market Opportunity4.3 Premature Ejaculation Treatment Market - Supply Chain Analysis4.3.1 List of Key Suppliers4.3.2 List of Key Distributors4.3.3 List of Key Consumers4.4 Key Forces Shaping the Premature Ejaculation Treatment Market4.4.1 Bargaining Power of Suppliers4.4.2 Bargaining Power of Buyers4.4.3 Threat of Substitution4.4.4 Threat of New Entrants4.4.5 Competitive Rivalry4.5 Global Premature Ejaculation Treatment Market Size & Forecast, 2025-20344.5.1 Premature Ejaculation Treatment Market Size and Y-o-Y Growth4.5.2 Premature Ejaculation Treatment Market Absolute $ OpportunityChapter 5 Global Premature Ejaculation Treatment Market Analysis and Forecast By Treatment Type5.1 Introduction5.1.1 Key Market Trends & Growth Opportunities By Treatment Type5.1.2 Basis Point Share (BPS) Analysis By Treatment Type5.1.3 Absolute $ Opportunity Assessment By Treatment Type5.2 Premature Ejaculation Treatment Market Size Forecast By Treatment Type5.2.1 Pharmaceutical5.2.2 Behavioral Therapy5.2.3 Devices5.3 Market Attractiveness Analysis By Treatment TypeChapter 6 Global Premature Ejaculation Treatment Market Analysis and Forecast By Distribution Channel6.1 Introduction6.1.1 Key Market Trends & Growth Opportunities By Distribution Channel6.1.2 Basis Point Share (BPS) Analysis By Distribution Channel6.1.3 Absolute $ Opportunity Assessment By Distribution Channel6.2 Premature Ejaculation Treatment Market Size Forecast By Distribution Channel6.2.1 Hospitals6.2.2 Clinics6.2.3 Online Pharmacies6.2.4 Retail Pharmacies6.3 Market Attractiveness Analysis By Distribution ChannelChapter 7 Global Premature Ejaculation Treatment Market Analysis and Forecast By End-User7.1 Introduction7.1.1 Key Market Trends & Growth Opportunities By End-User7.1.2 Basis Point Share (BPS) Analysis By End-User7.1.3 Absolute $ Opportunity Assessment By End-User7.2 Premature Ejaculation Treatment Market Size Forecast By End-User7.2.1 Men7.2.2 Healthcare Providers7.3 Market Attractiveness Analysis By End-UserChapter 8 Global Premature Ejaculation Treatment Market Analysis and Forecast by Region8.1 Introduction8.1.1 Key Market Trends & Growth Opportunities By Region8.1.2 Basis Point Share (BPS) Analysis By Region8.1.3 Absolute $ Opportunity Assessment By Region8.2 Premature Ejaculation Treatment Market Size Forecast By Region8.2.1 North America8.2.2 Europe8.2.3 Asia Pacific8.2.4 Latin America8.2.5 Middle East & Africa (MEA)8.3 Market Attractiveness Analysis By RegionChapter 9 Coronavirus Disease (COVID-19) Impact9.1 Introduction9.2 Current & Future Impact Analysis9.3 Economic Impact Analysis9.4 Government Policies9.5 Investment ScenarioChapter 10 North America Premature Ejaculation Treatment Analysis and Forecast10.1 Introduction10.2 North America Premature Ejaculation Treatment Market Size Forecast by Country10.2.1 U.S.10.2.2 Canada10.3 Basis Point Share (BPS) Analysis by Country10.4 Absolute $ Opportunity Assessment by Country10.5 Market Attractiveness Analysis by Country10.6 North America Premature Ejaculation Treatment Market Size Forecast By Treatment Type10.6.1 Pharmaceutical10.6.2 Behavioral Therapy10.6.3 Devices10.7 Basis Point Share (BPS) Analysis By Treatment Type10.8 Absolute $ Opportunity Assessment By Treatment Type10.9 Market Attractiveness Analysis By Treatment Type10.10 North America Premature Ejaculation Treatment Market Size Forecast By Distribution Channel10.10.1 Hospitals10.10.2 Clinics10.10.3 Online Pharmacies10.10.4 Retail Pharmacies10.11 Basis Point Share (BPS) Analysis By Distribution Channel10.12 Absolute $ Opportunity Assessment By Distribution Channel10.13 Market Attractiveness Analysis By Distribution Channel10.14 North America Premature Ejaculation Treatment Market Size Forecast By End-User10.14.1 Men10.14.2 Healthcare Providers10.15 Basis Point Share (BPS) Analysis By End-User10.16 Absolute $ Opportunity Assessment By End-User10.17 Market Attractiveness Analysis By End-UserChapter 11 Europe Premature Ejaculation Treatment Analysis and Forecast11.1 Introduction11.2 Europe Premature Ejaculation Treatment Market Size Forecast by Country11.2.1 Germany11.2.2 France11.2.3 Italy11.2.4 U.K.11.2.5 Spain11.2.6 Russia11.2.7 Rest of Europe11.3 Basis Point Share (BPS) Analysis by Country11.4 Absolute $ Opportunity Assessment by Country11.5 Market Attractiveness Analysis by Country11.6 Europe Premature Ejaculation Treatment Market Size Forecast By Treatment Type11.6.1 Pharmaceutical11.6.2 Behavioral Therapy11.6.3 Devices11.7 Basis Point Share (BPS) Analysis By Treatment Type11.8 Absolute $ Opportunity Assessment By Treatment Type11.9 Market Attractiveness Analysis By Treatment Type11.10 Europe Premature Ejaculation Treatment Market Size Forecast By Distribution Channel11.10.1 Hospitals11.10.2 Clinics11.10.3 Online Pharmacies11.10.4 Retail Pharmacies11.11 Basis Point Share (BPS)